

FOR IMMEDIATE RELEASE:
July 26, 2005

Cynexus Contact:
Chad Kennedy, PhD
Cynexus Corp.
480.232.9320

Avio Contact:
Bruce Bridgewater
Avio Scientific, LLC
480.607.2998

Cynexus Corp. and Avio Scientific, LLC Announce A Joint Venture Agreement

Chandler, Arizona – July 26th, 2005 – Cynexus Corporation today has announced that it has entered into a joint venture agreement with Avio Scientific, LLC for the development of non-fouling medical device coatings. The alliance will initially focus on device coatings for the ophthalmic market. Under the terms of the agreement, Avio Scientific, headquartered in Scottsdale, Arizona, will have exclusive rights to market and distribute the developed ophthalmic products.

“We’re extremely excited to be jointly working with Avio toward advancing the future of medical device coating technologies,” said Chad Kennedy, PhD, president and chief executive officer of Cynexus. “We see a world of potential not just in ophthalmic applications but in a myriad of other implantable devices as well.”

Cynexus plans for the initial research and development to lead to breakthrough anti-inflammatory and anti-bacterial coatings for ophthalmic, orthopedic, cardiovascular and other device implants with far superior performance to what is in the marketplace today.

“We believe that Cynexus’ coating technologies address the most common causes of medical device failure in the ophthalmic industry,” says Bruce Bridgewater, OD, president of Avio Scientific. “We believe the ophthalmic industry offers many high growth product opportunities, with relatively modest regulatory hurdles,” says Dr. Bridgewater.

Avio expects to target contact lens, surgical, refractive surgical, and dry eye applications with Cynexus’ evolving technology.

ABOUT CYNEXUS CORPORATION

Cynexus is a biotherapeutics company that is dedicated to developing and commercializing product solutions for the underserved, inflammation disease marketplace. The company’s breakthrough technology offers significant competitive advantages within its target applications because of its unique cell blocking action and persistence capabilities. Cynexus expects to become a recognized innovator solving inflammation related problems, such as dry eye disease, allergy induced eye inflammation and multiple medical device and implant applications.

ABOUT AVIO SCIENTIFIC, LLC

Avio Scientific is committed to commercializing novel technologies that address existing limitations, or service underserved opportunities, within the ophthalmic industry. Utilizing an established industry presence, Avio will first bring to market products based upon a breakthrough medical device coating technology, developed by the principals of Cynexus Corp. Avio Scientific believes that this technology will markedly improve the performance of ophthalmic medical devices and expects to attract corporate partners to facilitate commercial efforts.

For more information contact Cynexus Corp. by phone 480.232.9320, fax 480.324.1250 or email at questions@cynexus.com. Avio Scientific, LLC by phone 480.607.2998, fax 480.607.2871, or mail 7642 E. Gray Rd., Suite 103, Scottsdale, AZ 85260.

###